Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Shares Issued (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Shares Issued for 5 consecutive years, with $41000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued changed N/A to $41000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 91.63% decrease, with the full-year FY2024 number at $23.6 million, up 28.63% from a year prior.
  • Shares Issued was $41000.0 for Q2 2025 at Werewolf Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $21.1 million in Q3 2024 to a low of -$3.7 million in Q3 2022.
  • A 5-year average of $3.2 million and a median of $254000.0 in 2022 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 53958.97% in 2024; the steepest drop was 99.86% in 2024.
  • Werewolf Therapeutics' Shares Issued stood at -$21000.0 in 2021, then skyrocketed by 1309.52% to $254000.0 in 2022, then soared by 3453.15% to $9.0 million in 2023, then crashed by 72.51% to $2.5 million in 2024, then plummeted by 98.35% to $41000.0 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Shares Issued are $41000.0 (Q2 2025), $2.5 million (Q4 2024), and $21.1 million (Q3 2024).